AU2018330444B2 - Interleukin-18 variants and methods of use - Google Patents

Interleukin-18 variants and methods of use Download PDF

Info

Publication number
AU2018330444B2
AU2018330444B2 AU2018330444A AU2018330444A AU2018330444B2 AU 2018330444 B2 AU2018330444 B2 AU 2018330444B2 AU 2018330444 A AU2018330444 A AU 2018330444A AU 2018330444 A AU2018330444 A AU 2018330444A AU 2018330444 B2 AU2018330444 B2 AU 2018330444B2
Authority
AU
Australia
Prior art keywords
seq
variant
variant polypeptide
polypeptide
relative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018330444A
Other languages
English (en)
Other versions
AU2018330444A1 (en
Inventor
Suzanne Fischer
Aaron RING
Ting Zhou
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of AU2018330444A1 publication Critical patent/AU2018330444A1/en
Application granted granted Critical
Publication of AU2018330444B2 publication Critical patent/AU2018330444B2/en
Priority to AU2023266285A priority Critical patent/AU2023266285A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/642—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a cytokine, e.g. IL2, chemokine, growth factors or interferons being the inactive part of the conjugate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU2018330444A 2017-09-06 2018-09-06 Interleukin-18 variants and methods of use Active AU2018330444B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2023266285A AU2023266285A1 (en) 2017-09-06 2023-11-15 Interleukin-18 variants and methods of use

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762554605P 2017-09-06 2017-09-06
US62/554,605 2017-09-06
US201862652279P 2018-04-03 2018-04-03
US62/652,279 2018-04-03
PCT/US2018/049648 WO2019051015A1 (en) 2017-09-06 2018-09-06 VARIANTS OF INTERLEUKIN-18 AND METHODS OF USE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2023266285A Division AU2023266285A1 (en) 2017-09-06 2023-11-15 Interleukin-18 variants and methods of use

Publications (2)

Publication Number Publication Date
AU2018330444A1 AU2018330444A1 (en) 2020-04-23
AU2018330444B2 true AU2018330444B2 (en) 2023-08-17

Family

ID=65517760

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018330444A Active AU2018330444B2 (en) 2017-09-06 2018-09-06 Interleukin-18 variants and methods of use
AU2023266285A Abandoned AU2023266285A1 (en) 2017-09-06 2023-11-15 Interleukin-18 variants and methods of use

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2023266285A Abandoned AU2023266285A1 (en) 2017-09-06 2023-11-15 Interleukin-18 variants and methods of use

Country Status (13)

Country Link
US (6) US20190070262A1 (enExample)
EP (1) EP3678681A4 (enExample)
JP (2) JP2020533301A (enExample)
KR (1) KR20200066623A (enExample)
CN (1) CN111315395A (enExample)
AU (2) AU2018330444B2 (enExample)
BR (1) BR112020004389A2 (enExample)
CA (1) CA3080492A1 (enExample)
IL (2) IL272635B2 (enExample)
MX (1) MX2020002542A (enExample)
SG (1) SG11202001384TA (enExample)
WO (1) WO2019051015A1 (enExample)
ZA (1) ZA202307212B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12029778B2 (en) 2019-05-13 2024-07-09 Yale University Interleukin-18 mimics and methods of use
MX2022014239A (es) * 2020-05-12 2023-02-09 Regeneron Pharma Nuevos agonistas de il10 y metodos para su uso.
CA3189327A1 (en) * 2020-08-19 2022-02-24 Vijaya Raghavan PATTABIRAMAN Modified il-18 polypeptides and uses thereof
IL302517A (en) * 2020-11-02 2023-07-01 Simcha Il 18 Inc Variants of interleukin-18 and methods of use
EP4293039A4 (en) * 2021-02-10 2025-07-16 Univ Nagasaki NEW VARIANT OF HUMAN INTERLEUKIN-18 AND ITS USE
US20230146665A1 (en) 2021-07-27 2023-05-11 Xencor, Inc. Il-18-fc fusion proteins
JP2023024168A (ja) 2021-08-06 2023-02-16 国立大学法人 長崎大学 がんの治療剤
AU2022414067A1 (en) 2021-12-15 2024-05-23 Genentech, Inc. Stabilized il-18 polypeptides and uses thereof
WO2023118497A1 (en) * 2021-12-22 2023-06-29 Pieris Pharmaceuticals Gmbh Novel il-18 variants
CN119053347A (zh) 2022-02-23 2024-11-29 明峰治疗股份公司 免疫抗原特异性il-18免疫细胞因子及其用途
CA3244052A1 (en) * 2022-02-23 2023-08-31 Bright Peak Therapeutics Ag ACTIVABLE IL-18 POLYPEPTIDES
CA3244053A1 (en) * 2022-02-23 2023-08-31 Bright Peak Therapeutics Ag Modified il-18 polypeptides
JP2025509832A (ja) 2022-03-15 2025-04-11 コンピュジェン リミテッド Ｉｌ－１８ｂｐアンタゴニスト抗体、並びに癌の治療での単剤療法及び併用療法におけるそれらの使用
EP4519678A1 (en) * 2022-05-05 2025-03-12 Hospital Espanol Auxilio Mutuo de Puerto Rico, Inc. Methods for treating bladder cancer
CN120051292A (zh) * 2022-08-05 2025-05-27 融合生物疗法公司 Il-18融合蛋白以及生产il-18的方法
WO2024044780A1 (en) * 2022-08-26 2024-02-29 Sutro Biopharma, Inc. Interleukin-18 variants and uses thereof
JP2025529313A (ja) * 2022-09-06 2025-09-04 ティージェイ バイオファーマ （シャンハイ） カンパニー， リミテッド Ｉｌ－１８バリアントポリペプチド
EP4604988A1 (en) * 2022-10-21 2025-08-27 Diagonal Therapeutics Inc. Heteromeric agonistic antibodies to il-18 receptor
WO2024102693A2 (en) 2022-11-07 2024-05-16 Xencor, Inc. Il-18-fc fusion proteins
CN118141897A (zh) 2022-12-07 2024-06-07 广州威溶特医药科技有限公司 Dr-18和溶瘤痘苗病毒在制备抗肿瘤药物中的应用
CN120530131A (zh) * 2023-01-06 2025-08-22 拉森医疗公司 抗il-18bp抗体
EP4646270A2 (en) * 2023-01-06 2025-11-12 Alector LLC Anti-il18 binding protein antibodies and methods of use thereof
TW202430560A (zh) * 2023-01-06 2024-08-01 美商拉森醫療公司 抗ｉｌ－１８ｂｐ抗體
CN121079314A (zh) * 2023-01-24 2025-12-05 辛查 Il-18 公司 用于组合疗法的方法和组合物
WO2024251983A1 (en) * 2023-06-09 2024-12-12 Merck Patent Gmbh Il-18 mimetics
TW202515608A (zh) 2023-06-26 2025-04-16 以色列商坎布根有限公司 Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途
WO2025015103A1 (en) * 2023-07-10 2025-01-16 The Children's Hospital Of Philadelphia Methods for modulating activity of il-18 for treatment of cd4+ t cell mediated autoimmunity and immunopathology
WO2025041102A1 (en) 2023-08-23 2025-02-27 Bright Peak Therapeutics Ag Targeted immune activation with il-18 immunocytokines
WO2025041101A1 (en) 2023-08-23 2025-02-27 Bright Peak Therapeutics Ag Activatable il-18 immunocytokines and uses thereof
US20250188166A1 (en) 2023-08-23 2025-06-12 Bright Peak Therapeutics Ag Il-18 polypeptides fused to immune cell antigen specific binding polypeptides and uses thereof
WO2025068413A1 (en) 2023-09-28 2025-04-03 Prokarium Limited Interleukin 18 variants
WO2025085447A1 (en) 2023-10-17 2025-04-24 Xencor, Inc. Pd-1 targeted il18-fc fusion proteins
CN120093897A (zh) * 2023-12-04 2025-06-06 广州威溶特医药科技有限公司 Dr-18和单纯疱疹病毒在制备抗肿瘤药物中的应用
CN120189493A (zh) 2023-12-22 2025-06-24 广州威溶特医药科技有限公司 Dr-18和m1病毒在制备抗肿瘤药物中的应用
US12134635B1 (en) 2023-12-29 2024-11-05 Sonnet BioTherapeutics, Inc. Interleukin 18 (IL-18) variants and fusion proteins comprising same
WO2025151273A1 (en) * 2024-01-08 2025-07-17 Adimab, Llc Il-18 polypeptides and uses thereof
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002101049A2 (en) * 2001-03-08 2002-12-19 Ares Trading S.A. Interleukin-18 mutants, their production and use

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6479258B1 (en) 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US6713279B1 (en) 1995-12-07 2004-03-30 Diversa Corporation Non-stochastic generation of genetic vaccines and enzymes
EP1669454A3 (en) * 1996-06-27 2009-04-01 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Genomic DNA encoding a polypeptide capable of inducing the production of interferon-gamma
US6790442B1 (en) 1996-06-27 2004-09-14 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Genomic DNA encoding a polypeptide capable of inducing the production of interferon-γ
JP4024366B2 (ja) 1996-11-29 2007-12-19 株式会社林原生物化学研究所 ポリペプチド
JP3955352B2 (ja) * 1997-02-25 2007-08-08 株式会社林原生物化学研究所 破骨細胞形成阻害剤
TWI227136B (en) * 1998-05-21 2005-02-01 Smithkline Beecham Corp Novel pharmaceutical composition for the prevention and/or treatment of cancer
JP2001266941A (ja) 2000-03-17 2001-09-28 Sony Corp ゲル電解質電池の製造方法
AU7516601A (en) * 2000-06-02 2001-12-17 Susan B Dillon Methods of treating viral diseases with il-18 and il-18 combinations
JP5121109B2 (ja) 2000-06-15 2013-01-16 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 生理的に活性なｉｌ−１８ポリペプチドの調製方法
US6818444B2 (en) 2000-08-04 2004-11-16 Heska Corporation Canine and feline proteins, nucleic acid molecules and uses thereof
DE60238532D1 (de) 2001-05-04 2011-01-20 Cornell Res Foundation Inc Schnell spaltbares sumofusionsprotein-expressionssystem für schwer zu exprimierende proteine
BR0206112A (pt) 2001-10-10 2005-05-10 Centocor Inc Vacinas de ácido nucléico usando ácidos nucléicos de codificação de antìgeno de tumor com ácido nucleìco de codificação de auxiliar de citocina
WO2003057821A2 (en) 2001-10-26 2003-07-17 Centocor, Inc. Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses
US6800479B2 (en) 2001-12-11 2004-10-05 Samyang Genex Corporation Recombinant adenoviruses expressing interleukin-18 protein and gene therapy using them
US7220576B2 (en) 2002-01-07 2007-05-22 Lifesensors, Inc. Methods and compositions for protein expression and purification
US7060461B2 (en) 2002-01-07 2006-06-13 Lifesensors, Inc. Methods and compositions for protein expression and purification
US7253260B2 (en) 2002-04-17 2007-08-07 Smithkline Beecham Corporation Human IL-18 crystal structure
US20050153880A1 (en) * 2002-06-27 2005-07-14 Yukio Goto Methods of treating or preventing ibd with il-18
BR0315155A (pt) * 2002-10-08 2005-08-16 Ares Trading Sa Uso de citocina capaz de ligar il-18bp e de inibir a atividade de uma segunda citocina
EP1613274B1 (en) * 2003-04-15 2010-03-03 GlaxoSmithKline LLC Human il-18 substitution mutants and their conjugates
US20080076708A1 (en) * 2003-05-13 2008-03-27 Valter Altarocca Active Variants of the Il-18 Binding Protein and Medical Uses Thereof
AU2004254600A1 (en) 2003-06-26 2005-01-13 Lifesensors, Inc. Methods and compositions for enhanced protein expression and purification
DE602004031341D1 (de) 2003-07-21 2011-03-24 Transgene Sa Multifunktionelle cytokine
DE602004031681D1 (de) * 2003-07-21 2011-04-14 Transgene Sa Multifunktionelle Cytokine
WO2005075648A1 (en) * 2004-01-28 2005-08-18 Gifu University Interleukin-18 mutant proteins
AU2005277404A1 (en) 2004-08-20 2006-03-02 Smithkline Beecham Corporation Methods of healing wounds by administering human IL-18
EP1836214A4 (en) 2004-12-30 2009-01-21 Lifesensors Inc COMPOSITIONS, METHODS, AND KITS FOR IMPROVING PROTEIN EXPRESSION, SOLUBILITY, AND ISOLATION
CA2662609A1 (en) 2006-09-14 2008-03-20 The Trustees Of The University Of Pennsylvania Modulation of regulatory t cells by human il-18
US8691958B2 (en) 2006-12-29 2014-04-08 Progenra, Inc. Methods and compositions for enhanced protein expression and purification
HUE038588T2 (hu) 2007-11-07 2018-10-29 Genentech Inc IL-22 mikrobiális rendellenességek kezelésében történõ alkalmazásra
WO2009107458A1 (ja) 2008-02-27 2009-09-03 シャープ株式会社 照明装置、表示装置及びテレビ受信装置
US8034910B2 (en) 2008-05-06 2011-10-11 Academia Sinica, Taiwan SUMO fusion protein expression system for producing native proteins
CN101993495B (zh) 2009-08-12 2013-07-24 上海近岸科技有限公司 一种蛋白质混合物及其制备方法
US9316417B2 (en) 2012-06-29 2016-04-19 Sunpower Corporation Framing system for mounting solar collecting devices
RU2015106812A (ru) 2012-08-02 2016-09-27 Ф.Хоффманн-Ля Рош Аг Способ получения мономерных и мультимерных молекул и их применение
JOP20200308A1 (ar) * 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
US10646548B2 (en) 2013-10-08 2020-05-12 Georgia State University Research Foundation, Inc. Compositions including IL-18 and IL-22 and their use in anti-viral therapies
SG11201706879UA (en) 2015-03-05 2017-09-28 Ab2 Bio Sa Il-18 binding protein (il-18bp) and antibodies in inflammatory diseases
AU2016251687C1 (en) 2015-04-22 2023-07-27 CureVac SE RNA containing composition for treatment of tumor diseases
WO2017102010A1 (en) * 2015-12-17 2017-06-22 Biontech Rna Pharmaceuticals Gmbh Novel cytokine fusion proteins
EP3411414A4 (en) 2016-02-05 2019-10-23 Washington University COMPOSITIONS AND METHOD FOR TARGETED CYTOKINE RELIEF
US11291721B2 (en) 2016-03-21 2022-04-05 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
ITUA20161992A1 (it) 2016-03-24 2017-09-24 Plico Biotech Inc Sumo e suoi utilizzi
CA3032838A1 (en) 2016-08-04 2018-02-08 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
JP2019529499A (ja) 2016-09-30 2019-10-17 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ 組織指向性発現を用いた抗体ベースの遺伝子治療
TWI591177B (zh) 2016-10-27 2017-07-11 中化合成生技股份有限公司 一種胰高血糖素胜肽－２（ｇｌｐ－２）類似物的製備方法
CA3055318C (en) 2017-03-06 2025-11-25 Altor Bioscience Corp Il-15-based fusions to il-12 and il-18
CA3069105A1 (en) 2017-07-03 2019-01-10 Torque Therapeutics, Inc. Polynucleotides encoding immunostimulatory fusion molecules and uses thereof
CN112105736A (zh) 2018-05-04 2020-12-18 西格马-奥尔德里奇有限责任公司 生产具有降低宿主细胞蛋白水平的重组蛋白
NZ772550A (en) 2018-08-30 2025-08-29 Immunitybio Inc Multi-chain chimeric polypeptides and uses thereof
CN120535649A (zh) 2018-08-30 2025-08-26 免疫生物公司 单链嵌合多肽和其用途
CN112888445B (zh) 2018-08-30 2025-06-10 免疫生物公司 治疗老年化相关病症的方法
WO2020142720A1 (en) 2019-01-04 2020-07-09 Cogen Immune Medicine, Inc. Methods of producing high diversity peptide libraries and promoting protein folding
EP3969035A4 (en) 2019-05-14 2023-06-21 Werewolf Therapeutics, Inc. SEPARATION UNITS AND METHODS AND THEIR USE
WO2020243371A1 (en) 2019-05-28 2020-12-03 Massachusetts Institute Of Technology Methods and compositions for modulating immune responses
EP3976068A4 (en) 2019-05-31 2023-08-09 Children's National Medical Center CYTOKINE COCKTAILS FOR SELECTIVE T-LYMPHOCYTE SUBSET EXPANSION
US20230000913A1 (en) 2019-08-13 2023-01-05 King's College London Immunoresponsive cells armoured with spatiotemporally restricted activity of cytokines of the il-1 superfamily
WO2021072211A1 (en) 2019-10-09 2021-04-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating cytotoxic t cell resistant tumors
KR20230084470A (ko) 2020-08-14 2023-06-13 카이트 파마 인코포레이티드 면역 세포 기능의 향상
CA3189327A1 (en) 2020-08-19 2022-02-24 Vijaya Raghavan PATTABIRAMAN Modified il-18 polypeptides and uses thereof
IL302517A (en) 2020-11-02 2023-07-01 Simcha Il 18 Inc Variants of interleukin-18 and methods of use
IL308012A (en) 2021-04-30 2023-12-01 Cellectis Sa Anti-MUC1 for novel chimeric antigen receptors and genetically engineered immune cells for solid tumor immunotherapy
US20250281638A1 (en) 2021-06-10 2025-09-11 Chimera Bioengineering, Inc. Compositions and Methods for Activating Natural Killer Cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002101049A2 (en) * 2001-03-08 2002-12-19 Ares Trading S.A. Interleukin-18 mutants, their production and use

Also Published As

Publication number Publication date
CN111315395A (zh) 2020-06-19
BR112020004389A2 (pt) 2020-09-08
RU2020112538A (ru) 2021-10-06
IL272635B1 (en) 2023-10-01
ZA202307212B (en) 2024-10-30
JP2023157959A (ja) 2023-10-26
US12403180B2 (en) 2025-09-02
CA3080492A1 (en) 2019-03-14
IL272635B2 (en) 2024-02-01
US20230321192A1 (en) 2023-10-12
IL272635A (en) 2020-03-31
KR20200066623A (ko) 2020-06-10
JP2020533301A (ja) 2020-11-19
US20240325494A1 (en) 2024-10-03
AU2023266285A1 (en) 2024-01-25
US20230355714A1 (en) 2023-11-09
WO2019051015A1 (en) 2019-03-14
MX2020002542A (es) 2020-07-20
IL305370A (en) 2023-10-01
AU2018330444A1 (en) 2020-04-23
EP3678681A4 (en) 2021-07-14
US20230241172A1 (en) 2023-08-03
US20190070262A1 (en) 2019-03-07
SG11202001384TA (en) 2020-03-30
RU2020112538A3 (enExample) 2022-04-04
EP3678681A1 (en) 2020-07-15
US20250057918A1 (en) 2025-02-20
US12343379B2 (en) 2025-07-01

Similar Documents

Publication Publication Date Title
US12403180B2 (en) Interleukin-18 variants and methods of use
US11850276B2 (en) Interleukin-18 variants and methods of use
US12029778B2 (en) Interleukin-18 mimics and methods of use
JP2020096630A5 (enExample)
EP4556486A1 (en) Trispecific antibody and use thereof
US20240342246A1 (en) Interleukin-12 variants and methods of use
RU2797536C2 (ru) Варианты интерлейкина-18 и способы их применения

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)